Umbilical Cord Blood Treatment for Refractory Immune Cytopenia: a Single-arm Prospective Study
Immune-related hematocytopenia is a type of immunity Inflammatory cytopenia-mediated diseases, hormones and immunosuppressants are its first-line treatment. However, conventional immunosuppressants are ineffective or have a high recurrence rate. And some patients are not effective for these treatments, due to infection of blood cells, bleeding, decreased quality of life, and even severe death. There is currently no effective method for such patients. This study intends to recruit IRIC patients, give cord blood infusion, observe its efficacy and safety, and detect changes in inflammation-related indicators before and after treatment. There are no relevant reports at China and abroad. This study can provide new treatment options for patients with IRIC.
NCT04420494 — Umbilical Cord Blood
Status: Recruiting
http://inclinicaltrials.com/umbilical-cord-blood/NCT04420494/
the Effect of PRP and Cord Blood in Improving the Symptoms of Covid-19
covid - 19 is a critical viral infection that affects humans
NCT04393415 — Virus
Status: Recruiting
http://inclinicaltrials.com/virus/NCT04393415/
Autologous Cord Blood Cells for Prevention of BPD in Preterm
To study the effect of Autologous cord blood cells infusion on prevention of bronchopulmonary dysplasia in very preterm neonates
NCT04311476 — Safety Issues
Status: Completed
http://inclinicaltrials.com/safety-issues/NCT04311476/
Treatment of Children With Cerebral Palsy With Autologous Umbilical Cord Blood, a Pilot Study
This study is a phase II, prospective, double blind, placebo-controlled study of the efficacy of autologous umbilical cord blood infusion. The study population will consist of 72 children ages 2 months to 12 years with cerebral palsy. The population will be randomly assigned to 2 groups, 36 children in each group. The study group be treated by cord blood in the beginning of the study and the control group by placebo product. The study population will be stratified to reduce variance 3 groups by age: 2-12 months / 1-6 years / 6-12 years The study will consist of 4 stages Stage 1: initial assessment by physiotherapist and occupational therapist / treatment by cord blood or placebo / blood work before and after treatment Stage 2: at stage 1 + 3 months assessment by physiotherapist and occupational therapist Stage 3: at stage 1 + 6 months assessment by physiotherapist and occupational therapist / cross-over treatment by cord blood or placebo / blood work before and after treatment Stage 4: at stage 1 + 12 months assessment by physiotherapist and occupational therapist The primary outcome is improvement motor skills six months after treatment at stage 3
NCT04243408 — Cerebral Palsy
Status: Recruiting
http://inclinicaltrials.com/cerebral-palsy/NCT04243408/
Treatment of Children With Autistic Spectrum Disorder With Autologous Umbilical Cord Blood, a Pilot Study
This study is a phase II, prospective, double blind, placebo-controlled study of the efficacy of autologous umbilical cord blood infusion. The study population will consist of 60 children ages 18 months to 12 years with ASD. The population will be randomly assigned to 2 groups, the study group be treated by cord blood in the beginning of the study and the control group by placebo product. The study will consist of 4 stages Stage 1: initial assessment by physiotherapist and occupational therapist / treatment by cord blood or placebo / blood work before and after treatment Stage 2: at stage 1 + 6 months assessment by physiotherapist and occupational therapist / cross-over treatment by cord blood or placebo / blood work before and after treatment Stage 4: at stage 1 + 12 months assessment by physiotherapist and occupational therapist The primary outcome is improvement of social communication skills six months after treatment at stage 1
NCT04243382 — Autistic Spectrum Disorder
Status: Recruiting
http://inclinicaltrials.com/autistic-spectrum-disorder/NCT04243382/
Cord Blood Microtransplantation for Treatment of Acute Myeloid Leukemia
Discuss the effectiveness and safety of cord blood microtransplantation for treatment of acute myeloid leukemia
NCT04174586 — Safety Issues
Status: Recruiting
http://inclinicaltrials.com/safety-issues/NCT04174586/
Multi-center Clinical Study of Cord Blood Stem Cell Transplantation for Severe Combined Immunodeficiency Disease
Severe combined immunodeficiency (SCID) is a rare disease caused by a group of genetic disorders that leads to early death from recurrent infections in affected children.The only curative therapy for SCID is allogeneic hematopoietic stem cell transplantation.Unrelated umbilical cord blood(UCB) is increasingly used as an alternative to bone marrow.
NCT04172181 — Severe Combined Immunodeficiency Disease
Status: Active, not recruiting
http://inclinicaltrials.com/severe-combined-immunodeficiency-disease/NCT04172181/
Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells to Facilitate the Engraftment of a Single CCR5Δ32 Homozygous or Heterozygous Cord Blood Unit in Patients With HIV and Hematological Malignancies
This phase II trial studies the side effects of a cord blood transplant using dilanubicel and to see how well it works in treating patients with human immunodeficiency virus (HIV) positive hematologic (blood) cancers. After a cord blood transplant, the immune cells, including white blood cells, can take a while to recover, putting the patient at increased risk of infection. Dilanubicel consists of blood stem cells that help to produce mature blood cells, including immune cells. Drugs used in chemotherapy, such as fludarabine, cyclophosphamide, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Total body irradiation is a type of whole-body radiation. Giving chemotherapy and total-body irradiation before a cord blood transplant with dilanubicel may help to kill any cancer cells that are in the body and make room in the patient's bone marrow for new stem cells to grow and reduce the risk of infection.
NCT04083170 — Acute Myeloid Leukemia
Status: Terminated
http://inclinicaltrials.com/acute-myeloid-leukemia/NCT04083170/
Effect of Residual Dental Pulp Tissue and Cord Blood Stem Cells on Regeneration of Dental
The experiments outlined in this proposal are designed to test the hypothesis that the in vivo injection of cord blood stem cells (InvitRx®) into the root canal system will facilitate teeth initially diagnosed with irreversible pulpitis, to form normal healthy pulpal tissue.
NCT04040127 — Irreversible Pulpitis
Status: Withdrawn
http://inclinicaltrials.com/irreversible-pulpitis/NCT04040127/
Safety and Efficacy of Combined Administration of Erythropoietin in Umbilical Cord Blood Therapy for Stroke Patients
This clinical trial is a clinical trial for the evaluation of the safety and efficacy of umbilical cord blood (UCB) therapy, UCB and erythropoietin (EPO) combination therapy in adult stroke patients.
NCT04013646 — Stroke
Status: Recruiting
http://inclinicaltrials.com/stroke/NCT04013646/